Christopher L. Lotz
CIK 1812553 · Vice President of Finance, CFO · last filed 2022-08-04
Christopher L. Lotz is a Vice President of Finance, CFO who has filed 4 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for QLGN, was dated Aug 4, 2022. Across all open-market trades the lifetime net is +$5.0K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
4
$5.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Qualigen Therapeutics, Inc. (QLGN) Delisted | Vice President of Finance, CFO | 12,541 | $3.21 | $40.3K | $5.0K | 4 | 2022-08-04 |
Recent Filings
4 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-04 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-04-19 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Buy (P) | +2,700 | $5.0K | EDGAR |
| 2020-06-08 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-27 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Other (J) | +9,841 | $0 | EDGAR |